MedTrace Logo

A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects

NCT06860282 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-03-06

No results posted yet for this study

Summary

This study is divided into two parts, including Part I: a randomized, open-label, positive drug-controlled, single ascending dose (SAD) study, a food effect (FE) study, and Part II: a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study.

Conditions

Interventions

DRUG

Remdesivir

Intravenous remdesivir 100 mg

DRUG

CX2101A

CX2101A enteric-coated tablet

DRUG

Placebo

CX2101A placebo enteric-coated tablet

Sponsors & Collaborators

  • Heronova Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-26
Primary Completion
2023-03-27
Completion
2023-03-27

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06860282 on ClinicalTrials.gov